Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii
Walter Reinisch(Medical University of Vienna), Séverine Vermeire(KU Leuven), Dino Tarabar(Military Medical Academy), Caleb Bliss(Takeda (United States)), William J. Sandborn(University of San Diego), Martina Goetsch(Pfizer (United States)), Tomáš Vaňásek, Fabio Cataldi(Pfizer (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), Paul Hellstern(Clinical Research Atlanta), Miles Sparrow(Alfred Health), Joo Sung Kim(National University College), Xavier Hébuterne, Kenneth J. Gorelick, Miloš Greguš, Maria Kłopocka(Nicolaus Copernicus University)
Cited by 1
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
|Clinical Gastroenterology and Hepatology|2006|906